Cellular Origins, a TTP Company, Appoints Peter Crossley as Chief Operating Officer

Product and technology innovator will build team to further develop and deliver Cellular Origins’ products for cell and gene therapy manufacture at scale -Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene…

Read MoreCellular Origins, a TTP Company, Appoints Peter Crossley as Chief Operating Officer

Peach State Health Plan and the Centene Foundation Announce $2.2 Million Commitment to Augusta University

, Peach State Health Plan, a care management organization that serves the needs of Georgians through a range of health insurance solutions and a wholly owned subsidiary of Centene Corporation (NYSE: CNC), and the Centene Foundation, the philanthropic arm of Centene Corporation, announced a $2.2 million funding…

Read MorePeach State Health Plan and the Centene Foundation Announce $2.2 Million Commitment to Augusta University

CENTENE CORPORATION TO HOST 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS EARNINGS CALL

 Centene Corporation (NYSE: CNC) issued a reminder today that it will release its 2023 fourth quarter and full year financial results at approximately 6 a.m. ET on Tuesday, February 6, 2024, and host a conference call at 8:30 a.m. ET to review the results.…

Read MoreCENTENE CORPORATION TO HOST 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS EARNINGS CALL

CENTENE CORPORATION ANNOUNCES APPOINTMENT OF MICHAEL A. CARSON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ITS MEDICARE BUSINESS

Current Wellcare President & CEO, Richard Fisher, will join the Operations leadership team under Centene Chief Operating Officer Susan Smith, bringing additional Medicare expertise into Centene’s core services operations Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier…

Read MoreCENTENE CORPORATION ANNOUNCES APPOINTMENT OF MICHAEL A. CARSON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ITS MEDICARE BUSINESS

Elevance Health Reports Results for Fourth Quarter and Full Year 2023; Sets Full Year 2024 Outlook

Indianapolis, IN – January 24, 2024 – Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2023 results. “We are pleased to have delivered another year of strong performance in 2023, enabled by our relentless focus on customer experience…

Read MoreElevance Health Reports Results for Fourth Quarter and Full Year 2023; Sets Full Year 2024 Outlook

Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of…

Read MoreMyomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

Global Automated Blood Tube Labelers and Specimen Transport Boxes Strategic Research Report 2024 – ResearchAndMarkets.com

-The “Automated Blood Tube Labelers and Specimen Transport Boxes – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. Global Automated Blood Tube Labelers and Specimen Transport Boxes Market to Reach $518.8 Million by 2030 The global market for Automated Blood Tube Labelers…

Read MoreGlobal Automated Blood Tube Labelers and Specimen Transport Boxes Strategic Research Report 2024 – ResearchAndMarkets.com

Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland

(Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, has officially broken ground on its new state-of-the-art manufacturing facility, located in Athenry, Co. Galway. This marks the first step in the realisation of this…

Read MoreDexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland

Kindeva Drug Delivery acquires Summit Biosciences, a company specializing in the development and manufacturing of nasally administered drugs

 Kindeva Drug Delivery (“Kindeva”), a global leader in drug and device combination products, today announced the acquisition of Summit Biosciences Inc. ( “Summit”), an intranasal drug development and manufacturing organization (CDMO), with its founding family shareholders. Established in 2009, Summit has a long history…

Read MoreKindeva Drug Delivery acquires Summit Biosciences, a company specializing in the development and manufacturing of nasally administered drugs